Minerva Neurosciences, Inc. (NERV) Stock

Minerva Neurosciences, Inc. (NERV) is a Healthcare stock trading at $4.43 (as of 2026-06-18), with a market capitalization of $228.75M and a trailing P/E of -0.1. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company developing and commercializing product candidates for central nervous system diseases. Its main candidates include roluperidone for schizophrenia and MIN-301 for Parkinson’s disease and other neurodegenerative disorders, with a license agreement with Mitsubishi Tanabe Pharma for development, sales, and import of roluperidone globally excluding Asia.

Valuation — source: SEC EDGAR (first-party)
Price$4.43
Market Cap$228.75M
P/E Ratio-0.1
EV / EBITDA-7.0
Price / Book-0.90
DCF Value (model)$-3.41
DCF Upside vs Price-177.0%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$948122.00
Net Margin-30947.8%
Return on Equity163.4%
Current Ratio17.65
Financial Health — source: SEC EDGAR
Altman Z-Score-8.87 (distress)
Valuation vs Sector & Industry
Stock P/E-0.1
Sector P/E (Healthcare)20.9
Industry P/E (Pharmaceutical Products)17.0
vs Sector-100.6%
vs Industry-100.8%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderFEDERATED HERMES, INC. ($30.81M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEORemy Luthringer
Employees8
CountryUS
IPO Date2014-07-01

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • C4 Therapeutics, Inc. (CCCC)
  • Neonc Technologies Holdings, Inc. (NTHI)
  • SAB Biotherapeutics, Inc. (SABS)
  • Arcturus Therapeutics Holdings Inc. (ARCT)
  • Alector, Inc. (ALEC)
  • Coherus Oncology, Inc. (CHRS)
  • Genelux Corporation (GNLX)
  • LifeVantage Corporation (LFVN)
NERV earnings history · NERV institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.